|
Volumn 89, Issue 3, 2016, Pages 537-538
|
Eculizumab in children with hemolytic uremic syndrome
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ECULIZUMAB;
CHILD;
COMPLEMENT DISORDER;
DRUG EFFICACY;
DRUG SAFETY;
FUNCTIONAL DISEASE;
GENETIC PREDISPOSITION;
HEMOLYTIC UREMIC SYNDROME;
HUMAN;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
PROGNOSIS;
PROSPECTIVE STUDY;
RECURRENT DISEASE;
RELAPSE;
REMISSION;
REVIEW;
SYMPTOM;
THROMBOTIC THROMBOCYTOPENIC PURPURA;
TREATMENT RESPONSE;
SAFETY;
ATYPICAL HEMOLYTIC UREMIC SYNDROME;
CHILD;
HEMOLYTIC-UREMIC SYNDROME;
HUMANS;
PROSPECTIVE STUDIES;
SAFETY;
|
EID: 84964533992
PISSN: 00852538
EISSN: 15231755
Source Type: Journal
DOI: 10.1016/j.kint.2015.12.039 Document Type: Note |
Times cited : (4)
|
References (8)
|